Compass Financial Management LLC Takes Position in ClearPoint Neuro, Inc. $CLPT

Compass Financial Management LLC bought a new position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 295,680 shares of the company’s stock, valued at approximately $5,275,000.

Several other hedge funds and other institutional investors have also modified their holdings of CLPT. SG Americas Securities LLC bought a new position in ClearPoint Neuro in the 1st quarter valued at about $3,388,000. Prescott Group Capital Management L.L.C. bought a new stake in shares of ClearPoint Neuro during the fourth quarter worth approximately $2,470,000. Deutsche Bank AG acquired a new position in shares of ClearPoint Neuro in the second quarter valued at approximately $2,048,000. BlackRock Inc. acquired a new position in shares of ClearPoint Neuro in the second quarter valued at approximately $42,456,000. Finally, Quantinno Capital Management LP increased its stake in shares of ClearPoint Neuro by 307.4% during the first quarter. Quantinno Capital Management LP now owns 51,947 shares of the company’s stock worth $473,000 after purchasing an additional 39,195 shares during the period. Institutional investors own 30.08% of the company’s stock.

Analyst Ratings Changes

CLPT has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Friday, July 17th. Stifel Nicolaus set a $22.00 price objective on ClearPoint Neuro in a report on Tuesday, August 4th. B. Riley Financial increased their price objective on ClearPoint Neuro from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. Wall Street Zen downgraded ClearPoint Neuro from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Finally, Lake Street Capital set a $25.00 target price on shares of ClearPoint Neuro in a research report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $25.67.

Insiders Place Their Bets

In other news, CEO Joseph Burnett sold 60,000 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $17.79, for a total transaction of $1,067,400.00. Following the completion of the sale, the chief executive officer directly owned 116,842 shares in the company, valued at approximately $2,078,619.18. This represents a 33.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 81,843 shares of company stock valued at $1,488,063. 6.94% of the stock is owned by insiders.

ClearPoint Neuro Stock Down 0.6%

Shares of CLPT opened at $13.96 on Friday. The company has a current ratio of 4.74, a quick ratio of 3.89 and a debt-to-equity ratio of 4.66. ClearPoint Neuro, Inc. has a 12 month low of $8.27 and a 12 month high of $30.10. The firm’s 50 day moving average is $15.62 and its 200-day moving average is $13.24. The stock has a market capitalization of $425.78 million, a PE ratio of -11.83 and a beta of 1.26.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.09). The company had revenue of $10.88 million during the quarter, compared to the consensus estimate of $12.73 million. ClearPoint Neuro had a negative net margin of 81.76% and a negative return on equity of 188.09%. During the same quarter last year, the firm posted ($0.21) earnings per share. Equities research analysts forecast that ClearPoint Neuro, Inc. will post -1.22 EPS for the current year.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.